{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"48.1","value":"23.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Time in weeks from the first administration of study drug to death.","dispersionType":"Full Range","groups":[{"description":"AZD4877 25 mg (Intravenous (IV), 25mg weekly)","id":"OG000","title":"AZD4877"}],"paramType":"MEDIAN","populationDescription":"Of the 41 participants who received at least one dose of study medication, only 39 were evaluable for response by RECIST (excludes 2 patients who had baseline scans performed more than 28 days before dosing).","reportingStatus":"POSTED","timeFrame":"Time from the first administration of study drug to disease progression or death (maximum treatment period of 309 days (44 weeks)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Weeks"}